ArticleCureus2025
Initial Investigation of Vericiguat Efficacy in the Treatment of Recurrently Hospitalised Heart Failure Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure is a global health problem that has led to an increase in hospitalisations, a decrease in quality of life and an increase in premature death. Rehospitalisation due to worsening heart failure is an indicator of poor prognosis and is directly correlated with life expectancy. Furthermore, additional hospitalisations increase the financial burden on medical systems.
objectiveThe objective of this study was to evaluate the effectiveness of the novel heart failure medication vericiguat in reducing hospitalisations and improving the clinical parameters of patients with heart failure with a reduced ejection fraction who are hospitalised with heart failure decompensation and need intravenous diuretics for decongestion. Additionally, reassure practitioners in vericiguat safety and efficiency to increase the number of patients receiving novel medications.
methodsWe conducted a retrospective observational study in patients with decompensated heart failure who were hospitalised at the Latvian Center of Cardiology. Data were collected for the period between November 2023 and November 2024, using patients' medical documentation. Vericiguat was initiated by physicians accordingly to the European guidelines on treating advanced heart failure. The aim of the study was to evaluate the effect of adding a novel medication on patients' hospitalisation rates and changes in clinical parameters. Clinical, echocardiographic and laboratory parameters were assessed during index hospitalisation and after one year with optimally tolerated medical therapy that included vericiguat. Statistical analysis was performed using SPSS version 22 (IBM Corp., Armonk, New York, USA).
resultsIn our study, more than half of the heart failure patients who received optimal medical treatment that included vericiguat were not rehospitalised and their condition did not worsen within 12 months of follow-up. With the optimisation of medical therapy and the addition of vericiguat, there was a statistically significant increase in the left ventricular ejection fraction and a statistically significant decrease in NT-proBNP levels.
conclusionsVericiguat can be added for the treatment of patients with a reduced ejection fraction and episodes of decompensation, showing promising results in decreasing additional hospitalisations and improving the clinical outcomes of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.